MedTrace Logo

Lurbinectedin in FET-Fused Tumors

NCT05918640 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2026-03-31

No results posted yet for this study

Summary

The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.

Conditions

  • Ewing Sarcoma
  • Desmoplastic Small Round Cell Tumor
  • Pediatric Cancer
  • Undifferentiated Sarcoma

Interventions

DRUG

Lurbinectedin

Lurbinectedin will be administered on a Day 1, Day 4 schedule every 21 days. Doses will be determined in the phase 1 portion of the trial.

Sponsors & Collaborators

Principal Investigators

  • Theodore Laetsch, MD · Children's Hospital of Philadelphia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-27
Primary Completion
2027-07-30
Completion
2028-07-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05918640 on ClinicalTrials.gov